Blogs
Explore the innovations shaping safer cell and gene therapies
What the FDA’s New Guidance Means for CRISPR off-Target Analysis
When the FDA released its draft guidance in April 2026 it marked an important step for the gene editing field. For the first time, developers had a detailed view of how the agency expects off-target risk to be assessed as programmes move towards the clinic.